Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Annexon, Inc. stock logo
ANNX
Annexon
$5.39
+1.5%
$5.64
$1.85
$7.18
$883.10M1.222.53 million shs3.82 million shs
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$29.13
+1.7%
$27.66
$15.35
$36.44
$3.00B2.262.02 million shs773,255 shs
Biogen Inc. stock logo
BIIB
Biogen
$192.58
-0.6%
$185.66
$121.05
$205.97
$28.43B0.191.29 million shs285,180 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,074.84
+0.9%
$944.65
$623.78
$1,133.95
$1.01T0.483.17 million shs1.65 million shs
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
$3.00
-2.3%
$3.24
$1.98
$6.55
$834.87M2.173.03 million shs2.14 million shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$30.80
-0.3%
$32.86
$22.96
$43.15
$3.58B0.722.71 million shs1.58 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Annexon, Inc. stock logo
ANNX
Annexon
0.00%+7.06%-9.69%+7.06%+151.66%
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
0.00%+6.83%+5.64%-11.30%+70.17%
Biogen Inc. stock logo
BIIB
Biogen
0.00%+0.96%+5.09%-0.70%+54.01%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%+7.87%+20.54%+2.29%+49.39%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
0.00%+0.99%-6.69%-27.42%+54.27%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
0.00%+7.67%-5.68%-8.47%+14.49%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Annexon, Inc. stock logo
ANNX
Annexon
$5.39
+1.5%
$5.64
$1.85
$7.18
$883.10M1.222.53 million shs3.82 million shs
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$29.13
+1.7%
$27.66
$15.35
$36.44
$3.00B2.262.02 million shs773,255 shs
Biogen Inc. stock logo
BIIB
Biogen
$192.58
-0.6%
$185.66
$121.05
$205.97
$28.43B0.191.29 million shs285,180 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,074.84
+0.9%
$944.65
$623.78
$1,133.95
$1.01T0.483.17 million shs1.65 million shs
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
$3.00
-2.3%
$3.24
$1.98
$6.55
$834.87M2.173.03 million shs2.14 million shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$30.80
-0.3%
$32.86
$22.96
$43.15
$3.58B0.722.71 million shs1.58 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Annexon, Inc. stock logo
ANNX
Annexon
0.00%+7.06%-9.69%+7.06%+151.66%
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
0.00%+6.83%+5.64%-11.30%+70.17%
Biogen Inc. stock logo
BIIB
Biogen
0.00%+0.96%+5.09%-0.70%+54.01%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%+7.87%+20.54%+2.29%+49.39%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
0.00%+0.99%-6.69%-27.42%+54.27%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
0.00%+7.67%-5.68%-8.47%+14.49%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Annexon, Inc. stock logo
ANNX
Annexon
2.43
Hold$16.00196.85% Upside
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
2.71
Moderate Buy$46.8360.77% Upside
Biogen Inc. stock logo
BIIB
Biogen
2.52
Moderate Buy$215.6211.96% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,227.0014.16% Upside
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
2.67
Moderate Buy$9.50216.67% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
2.85
Moderate Buy$95.50210.06% Upside

Current Analyst Ratings Breakdown

Latest LLY, VKTX, BIIB, SANA, BEAM, and ANNX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,133.00 ➝ $1,251.00
5/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Set Price Target$1,119.00
5/22/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingBuy$1,283.00
5/21/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform$1,350.00
5/21/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform
5/21/2026
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Reiterated RatingBuy$80.00
5/21/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price Target$1,300.00 ➝ $1,330.00
5/19/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
DowngradeBuy (B)Buy (B-)
5/15/2026
Biogen Inc. stock logo
BIIB
Biogen
Reiterated RatingOverweight$214.00 ➝ $225.00
5/15/2026
Biogen Inc. stock logo
BIIB
Biogen
Initiated CoverageOutperform
5/14/2026
Biogen Inc. stock logo
BIIB
Biogen
Reiterated RatingBuy
(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Annexon, Inc. stock logo
ANNX
Annexon
N/AN/AN/AN/A$1.25 per shareN/A
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$139.74M21.45N/AN/A$11.32 per share2.57
Biogen Inc. stock logo
BIIB
Biogen
$9.94B2.86$22.50 per share8.56$126.33 per share1.52
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B15.53$25.37 per share42.37$33.13 per share32.44
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/AN/AN/AN/A$0.43 per shareN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$4.32 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Annexon, Inc. stock logo
ANNX
Annexon
-$206.69M-$1.22N/AN/AN/AN/A-101.19%-75.99%8/13/2026 (Estimated)
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$79.99M-$0.68N/AN/AN/A-39.66%-29.00%-22.61%8/4/2026 (Estimated)
Biogen Inc. stock logo
BIIB
Biogen
$1.29B$9.3220.6611.631.7113.81%12.83%8.01%7/30/2026 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1538.1824.301.1634.98%105.77%23.76%8/5/2026 (Estimated)
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-$244.17M-$0.93N/AN/AN/AN/A-108.01%-40.68%8/10/2026 (Estimated)
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$359.64M-$4.14N/AN/AN/AN/A-71.31%-65.35%7/29/2026 (Estimated)

Latest LLY, VKTX, BIIB, SANA, BEAM, and ANNX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/11/2026Q1 2026
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-$0.15-$0.14+$0.01-$0.17N/AN/A
5/7/2026Q1 2026
Annexon, Inc. stock logo
ANNX
Annexon
-$0.30-$0.23+$0.07-$0.23$5.50 millionN/A
5/7/2026Q1 2026
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$1.0278-$0.91+$0.1178-$0.91$10.98 million$31.74 million
4/30/2026Q1 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.97$8.55+$1.58$8.26$17.82 billion$19.80 billion
4/29/2026Q1 2026
Biogen Inc. stock logo
BIIB
Biogen
$2.95$3.57+$0.62$2.15$2.29 billion$2.48 billion
4/29/2026Q1 2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$1.01-$1.37-$0.36-$1.37N/AN/A
3/30/2026Q4 2025
Annexon, Inc. stock logo
ANNX
Annexon
-$0.32-$0.28+$0.04-$0.28$3.25 millionN/A
3/3/2026Q4 2025
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
-$0.13-$0.16-$0.03-$0.21N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Annexon, Inc. stock logo
ANNX
Annexon
N/AN/AN/AN/AN/A
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
N/AN/AN/AN/AN/A
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.64%+15.18%24.58%11 Years
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A

Latest LLY, VKTX, BIIB, SANA, BEAM, and ANNX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.69%5/15/20265/15/20266/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Annexon, Inc. stock logo
ANNX
Annexon
N/A
6.35
6.35
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
0.09
16.99
16.99
Biogen Inc. stock logo
BIIB
Biogen
0.34
3.06
2.41
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
N/A
1.29
1.29
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
5.72
5.72

Institutional Ownership

CompanyInstitutional Ownership
Annexon, Inc. stock logo
ANNX
Annexon
N/A
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
99.68%
Biogen Inc. stock logo
BIIB
Biogen
87.93%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
88.23%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
Annexon, Inc. stock logo
ANNX
Annexon
60163.84 million144.40 millionOptionable
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
510102.88 million98.97 millionOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,500147.64 million147.27 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million940.42 millionOptionable
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
380278.29 million207.61 millionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
20116.11 million109.95 millionOptionable

Recent News About These Companies

If Viking Therapeutics Is Acquired, Here's Who Wins
Is Viking Therapeutics a Top Takeover Target?
Three Biotechs That Are Top Takeover Targets
LGND: 1Q:26 Results Highlight Breadth of Portfolio

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Annexon stock logo

Annexon NASDAQ:ANNX

$5.39 +0.08 (+1.51%)
As of 02:03 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Beam Therapeutics stock logo

Beam Therapeutics NASDAQ:BEAM

$29.13 +0.49 (+1.71%)
As of 02:04 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Biogen stock logo

Biogen NASDAQ:BIIB

$192.58 -1.18 (-0.61%)
As of 02:03 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,074.84 +9.84 (+0.92%)
As of 02:04 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Sana Biotechnology stock logo

Sana Biotechnology NASDAQ:SANA

$3.00 -0.07 (-2.28%)
As of 02:03 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$30.80 -0.09 (-0.29%)
As of 02:03 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.